Getinge AB Series B Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 1/30/2026)
| Balance Sheet | Total Assets | 56,505,000,000.00 | ROE | 52.08 % |
| Balance Sheet | Total Equity | 29,430,000,000.00 | ROA | 4.00 % |
| Cashflow | Capital Expenditures | -1,314,000,000.00 | P/FCF | 26.54 |
| Cashflow | Free Cash Flow | 2,635,000,064.00 | – | – |
| Cashflow | Operating Cash Flow | 3,949,000,000.00 | P/CF | 17.71 |
| Income | Earnings per Share (diluted) | 8.29 | Div. Yield | 1.85 % |
| Income | Net Income | 2,258,000,000.00 | P/E | 30.98 |
| Income | Shares Outstanding | 272,370,000.00 | P/B | 2.38 |
| Income | Total Revenue | 34,969,000,000.00 | P/S | 2.00 |
Ratios calculated on: 10/14/2026
Company Description
Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgery and life sciences in the hospital, pharmaceutical and research sectors. The company reports in three segments: Acute Therapies (63% of sales), Surgical Workflows (27%) and Life Sciences (10%). Product areas include ventilators, surgical stents, life support systems, sterilizers, operating tables and sterile transfer systems. Getinge generates its sales from a broad geographic presence, with the Americas accounting for 45% of sales (33% of sales in the US), 25% in the Asia-Pacific region and the remaining 30% in Europe, the Middle East and Africa.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.getinge.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more